ALXN - Alexion Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
Total Revenue
4,735,600
4,131,200
3,551,100
3,084,000
Cost of Revenue
377,000
374,300
454,200
258,000
Gross Profit
4,358,600
3,756,900
3,096,900
2,826,000
Operating Expenses
Research Development
822,000
730,400
878,400
757,000
Selling General and Administrative
1,198,800
1,111,800
1,094,400
954,000
Total Operating Expenses
2,336,500
2,162,300
2,292,900
2,033,000
Operating Income or Loss
2,022,100
1,594,600
804,000
793,000
Interest Expense
80,600
98,200
98,400
97,000
Total Other Income/Expenses Net
-397,600
-1,254,200
-157,800
-120,000
Income Before Tax
1,543,900
242,200
547,800
576,000
Income Tax Expense
73,600
164,600
104,500
177,000
Income from Continuing Operations
1,470,300
77,600
443,300
399,000
Net Income
1,470,300
77,600
443,300
399,000
Net Income available to common shareholders
1,470,300
77,600
443,300
399,000
Reported EPS
Basic
-
0.35
1.98
1.78
Diluted
-
0.35
1.97
1.76
Weighted average shares outstanding
Basic
-
222,700
223,900
224,000
Diluted
-
224,500
225,400
227,000
EBITDA
-
745,700
1,142,900
1,069,000